Every letter we have printed

The commercial literature describes maintenance as a phase; the trial literature describes it as an extension arm; the people I correspond with describe it as the rest of their life. Three timescales, one word, and most confusion in this area comes from the mismatch.

Where people give more than one reason, most analyses take the first mentioned, which is an ordering effect rather than a weighting. Asking respondents to rank would cost nothing and would change several published distributions.

The phrase lack of efficacy conceals two different things: no effect at all, and an effect that stopped being worth the effort. They have different implications and they are recorded under one heading.

I disagree with rather more of this than I expected to and I am glad it was printed. An argument I can take issue with is more use than a summary I cannot.

Retailers who buy from wholesalers display the wholesaler’s badge. The mark then describes material two steps removed from the vial being sold, and every party in the chain has behaved reasonably. Aggregation is where most of the misleading happens and no rule addresses it.

Sellers who cannot obtain a badge sometimes make their own. I have three in my collection that imitate a service’s house style closely enough to pass a glance and carry no link at all. The genuine mark has created a market for its own imitation.

Third-party custody is the answer and nobody will pay for it. A freight agent or a bonded store can hold and forward samples with a signed record for a modest fee, and I have never seen it used in this trade once.

Retained samples are the part I would add. Half the vial tested and half sealed and stored means a disputed result can be re-examined a year later, and it costs a freezer shelf. Almost no programme does it.

Material sold for research use is not approved for human use in any jurisdiction, and a discussion of ceilings in that context is a discussion about what has been studied rather than about what anybody should do. Your department is consistent on this and it is why I trust the rest of the coverage.

Exposure varies several-fold between individuals at the same nominal dose, which means a population ceiling and a personal one are different numbers. The pharmacokinetic variability is published and rarely quoted.

Trial protocols specify what to do after a missed administration, and those instructions are the closest thing to evidence-based guidance available. They are freely readable in the supplementary materials and almost never quoted.

The article assumes the baseline is a decision made once. On a shallow gradient with an absorbing mobile-phase additive it drifts through the run, and where the software anchors that drift moves small late peaks in and out of existence. Two analysts, same file, different answer, neither of them wrong.

The threshold discussion needs one more sentence. A reporting threshold and an integration threshold are different settings, and software will let you set them independently. A method can integrate down to 0.01 per cent and report nothing below 0.10 per cent, and the resulting certificate is honest, complete and impossible to compare with anything.

One practical note from the other side of the counter. When a customer asks us for the gradient we send it. When a customer asks a reseller, the reseller does not have it, because they were sent a PDF with a number on it. The gap you are describing is often two links down the chain rather than at the laboratory.

A certificate for a molecule is not a certificate for a vial. Where a supplier publishes one document per product rather than one per lot, the document is marketing with a chromatogram attached, however genuine the underlying determination was.

A note on the chain between synthesis and certificate. The document that matters is the one that names who took the sample and when. A report on a sample the seller chose, packed and posted describes that sample honestly and describes the lot only by assumption, and the assumption is the part nobody writes down.

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

Your anatomy of a certificate is the page I have pinned above the goods-in desk. The one field I would promote is the date of analysis as distinct from the date of issue. A certificate issued last month for a determination made two years ago is a true document about a lot that has since spent two years somewhere.

The published curves are almost always means with standard errors, which narrow as the sample grows and give an impression of precision about a population that says nothing about an individual. Standard deviations would be more honest and are rarely plotted.

The word plateau implies a stable state and what the data usually shows is a decelerating one. Those are different shapes with different implications for what happens next, and the distinction is lost in every summary I read.

I want to object to the framing of dose reduction as measurement. In practice it is experienced as failure, and telling people it is a thermostat does not change how the appointment feels. The language problem is real and you have solved it rhetorically rather than actually.

What is missing from the evidence base is any comparison of holding strategies. We have trials of schedules and no trials of the discretion applied to them, so every statement about how long to hold is extrapolation. Saying so plainly would be an improvement on most of what is written.

Intermittent use is studied almost nowhere and practised widely, which is an uncomfortable combination for anybody trying to write about it responsibly. The honest position is that the evidence base is close to empty, and saying so is more useful than assembling anecdotes.

The commonest reason for an intermittent pattern is supply or cost rather than design, which means much of what looks like a strategy is an accommodation. Reporting it as a strategy misdescribes what is happening.

Any account of maintenance that does not mention what happens to muscle over the same period is incomplete, and most do not. The composition literature and the maintenance literature are written by different people and rarely cite each other.

Where somebody discontinued and later resumed, most datasets record only the first event. The resumption is either lost or counted as a new entry, and the resulting rates describe a population with no memory.

A publication that keeps naming what is missing is doing something that cannot be done by a certificate, however good. The list of absent tests is editorial work rather than analytical work.

I asked four suppliers about this last year and all four answered plainly that it is not part of the standard panel and can be quoted separately. The silence is on the storefront rather than in the correspondence.

The test is inexpensive, it is available from ordinary contract laboratories, and it requires a small quantity of material. There is no technical reason it is absent from this trade and every commercial one.

The most useful sentence I have ever seen on a certificate read that the sample had been submitted by the customer and that the laboratory made no representation about its origin. It is a disclaimer, but it is an honest one, and it tells the reader exactly what the document does not cover.

Batch record and certificate answer different questions. The certificate says what a sample measured; the record says what the process did. A supplier that will send the second is offering a different kind of transparency from one that reissues the first on request.

On the recycling of a genuine document across later lots: this is the failure mode I meet most often in the wider market, and it is the hardest to characterise, because nothing on the page is false. The determination happened. It simply happened to a different batch than the one in the parcel.

The cloned-template problem is easy to detect and nobody does the detecting. Identical column identifiers, identical retention times to two decimals and different product names across four documents is not a coincidence, and it takes one careful reading to see. Buyers do not read certificates; they file them.

A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?

I have a certificate with an expiry date twenty-four months from manufacture and no stability data behind it, which your article says is a claim the documentation cannot support. The supplier tells me it is industry standard. Is it?

Storage conditions on a certificate should describe what the material was stored under before the determination, not what the buyer ought to do afterwards. The second is advice, the first is data, and the two are printed in the same box.

The abrupt stop in a withdrawal protocol is not how anybody stops in practice, which limits what the design can tell a reader about their own circumstances. The protocol is chosen for analytical clarity and the clarity is bought with realism.

Dropout after withdrawal is differential by definition: people in the withdrawal arm have less reason to attend. Any analysis that does not address that is measuring attendance as much as outcome.

What would help most is a clear statement of which questions have been studied at what horizon, in one table. Your reference desk does something close to this and it is more valuable than another analysis piece.

Nobody reports what maintenance costs in attention. The accounts I find most credible describe a low but continuous administrative load — ordering, storing, timing, monitoring — and that load is invisible in every clinical endpoint.